Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Candyse Brewer

Clinical Nurse Specialist, Gerontology Norman, OK Nurse Practitioner

NPI 1588263495 CMS profile 10867425

3500 Healthplex Pkwy Ste 200, Norman, OK 73072

Open in the dashboard

General payments

$3,553

203 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Candyse Brewer of Norman, OK is reported in the CMS Open Payments database as having received $3,553 across 203 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Clinical Nurse Specialist, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,039 68
2024 General $812 46
2023 General $983 55
2022 General $720 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Candyse Brewer
  • Clinical Nurse Specialist, Gerontology median
  • Middle half of Clinical Nurse Specialist, Gerontology
  • National median

In program year 2025, general payments to Candyse Brewer were reported at $1,039. Among 115 Clinical Nurse Specialist, Gerontology profiles paid that year, the median was $161 and the middle half received between $80 and $556.

Show as a table
Year Candyse Brewer Clinical Nurse Specialist, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $146 $38–$369 $132
2022 $720 $127 $48–$336 $149
2023 $983 $174 $43–$492 $160
2024 $812 $209 $72–$472 $164
2025 $1,039 $161 $80–$556 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $504 14 payments
  2. Amgen Inc. $453 41 payments
  3. Merck Sharp & Dohme Corporation $415 16 payments
  4. Abbott Laboratories $351 15 payments
  5. Pfizer Inc. $282 24 payments
  6. Janssen Pharmaceuticals, Inc $266 18 payments
  7. Novo Nordisk Inc $240 13 payments
  8. Novartis Pharmaceuticals Corporation $138 7 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $131 8 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $126 11 payments
  11. Other $648 36 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,542 202 payments
  2. Education $11 1 payment
Products named General payments · program years 2022–2025
  1. FARXIGA $324 8 payments
  2. Repatha Cardiology $305 23 payments
  3. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $271 12 payments
  4. XARELTO $266 18 payments
  5. VERQUVO Cardiovascular $263 13 payments
  6. WAINUA $217 5 payments
  7. Ozempic $202 11 payments
  8. VERQUVO Cardiovascular $171 6 payments
  9. RYBELSUS $161 9 payments
  10. REPATHA Cardiovascular $148 18 payments
  11. Other $1,962 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

5,926

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$896,829

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

26.5%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 434 $442,685
Farxiga Dapagliflozin Propanediol Brand 114 $128,201
Entresto Sacubitril/Valsartan Brand 85 $89,897
Xarelto Rivaroxaban Brand 73 $84,738
Brilinta Ticagrelor Brand 47 $36,770
Repatha Sureclick Evolocumab Brand 17 $20,199
Repatha Syringe Evolocumab Brand 20 $19,610
Metoprolol Succinate Generic 780 $12,284
Atorvastatin Calcium Generic 622 $9,219
Clopidogrel Clopidogrel Bisulfate Brand 492 $8,264

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$9,966

Medicare's payments for the services billed

Medicare patients

125

Average age 74

Services billed

229

85 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 45%
Diabetes 36%
Depression 36%
Atrial fibrillation 34%
Heart failure 28%
Chronic kidney disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $184
$184 37 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $129
$129 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $48
$48 114 —
VYNDAQEL
  • PFIZER INC. $41
$41 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

203 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Gerontology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record